Amarin: Could the New CEO Help Vazkepa’s European Push?
There’s a big change in Amarin’s (AMRN) C-Suite and it looks like
the Street is not happy about it. Shares took a beating in
Tuesday’s trading session after the biotech company announced the
departure of CEO John F. Thero. Thero who will retire on August 1,
has been with Amarin for twelve years, and at the helm for the last
seven. Karim Mikhail will take over his role. Mikhail is currently
the head of commercial for Europe and joined Amarin in 2020.
Mikhail held various executive roles at Merck and has considerable
expertise in bringing to market lipid therapies in the EU.